Cytokine Signatures of Immune Checkpoint Inhibitor Myocarditis and the Modifying Role of Clonal Hematopoiesis: A Machine-Learning and Multi-Omics Study
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Immune checkpoint inhibitor (ICI) myocarditis affects up to 2% of patients on ICI and has up to a 50% mortality. Clonal Hematopoiesis of Indeterminate Potential (CHIP) is a risk factor for ICI myocarditis.
Objectives
To leverage a multi-omics approach to evaluate cytokines associated with ICI myocarditis, immunosuppression resistance, CHIP in ICI myocarditis and implicated pathways and cell type contributions.
Methods
236 cardio-oncology patients were enrolled, including 88 who were on ICI. Cytokine profiling from patients on ICI were sampled and analyzed using machine learning and explainable artificial intelligence. Single-cell multi-omics of peripheral blood from Yale (n=19), Stanford (n=25), and MGH (n=63) evaluated cell-type contributions of cytokines and implicated pathways. Validation of Yale proteomic analyses was done using the Stanford CYTOF dataset.
Results
Top features associated with ICI myocarditis included IL13, CXCL10, PDGF-A, CCL13, CCL17 and KITlg. Top KEGG pathways associated with ICI myocarditis and immunosuppression resistant ICI myocarditis included JAK-STAT signaling, IL17 signaling and lipid/atherosclerosis pathways. At the single-cell level, the consensus signals distinguishing myocarditis from non-myocarditis across cohorts was predominantly driven by module-level JAK-STAT, T-cell, and Toll-like receptor activation. Similar transcription gene programs were activated in CHIP carriers including modules implicated in the pro-inflammatory immune response, such as NF-kappa B, IL17, MAPK, and TNF pathways within CHIP cells spanning lymphoid (cytotoxic CD8+ NKT, and natural killer cells) and myeloid lineages.
Conclusions
Across cohorts, JAK-STAT signaling emerges as a convergent and potentially actionable axis in ICI myocarditis that is further amplified in CHIP carriers, supporting cytokine-guided risk stratification and JAK-STAT–directed immunosuppression as testable strategies.